BioCryst Pharmaceuticals (BCRX) News Today $9.21 -0.18 (-1.92%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$9.07 -0.14 (-1.47%) As of 02/21/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on MondayFebruary 22 at 1:41 AM | americanbankingnews.comBioCryst Pharmaceuticals Inc (BCRX) Announces Participation in Upcoming Healthcare ConferencesFebruary 20 at 10:34 AM | gurufocus.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.50 Average PT from AnalystsFebruary 20 at 1:47 AM | americanbankingnews.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year High - Should You Buy?BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month High - Here's What HappenedFebruary 19 at 9:12 PM | marketbeat.comBioCryst to Present at Upcoming Investor ConferencesFebruary 19 at 7:00 AM | globenewswire.comRice Hall James & Associates LLC Sells 82,427 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Rice Hall James & Associates LLC lessened its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 3.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,081,316 shares of thFebruary 18, 2025 | marketbeat.comBioCryst Pharmaceuticals (BCRX) to Release Earnings on MondayBioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing earnings before the market opens on Monday, February 24, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=664409)February 17, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by AnalystsShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation andFebruary 17, 2025 | marketbeat.comBioCryst stock soars to 52-week high, touches $9.02February 14, 2025 | msn.comPortugal approves daily oral therapy for hereditary angioedemaFebruary 12, 2025 | msn.comBioCryst launches ORLADEYO in PortugalFebruary 12, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals Inc (BCRX) Gains Infarmed Recommendation for ORLADEYO in PortugalFebruary 12, 2025 | gurufocus.comBioCryst Launches ORLADEYO® (berotralstat) in PortugalFebruary 12, 2025 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 52-Week High - What's Next?BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year High - Here's WhyFebruary 12, 2025 | marketbeat.comBioCryst to present new ORLADEYO results from APeX-P pediatric trialFebruary 11, 2025 | markets.businessinsider.comBioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint CongressFebruary 10, 2025 | globenewswire.comBioCryst Pharmaceuticals Inc (BCRX) Announces Upcoming Fourth Quarter 2024 Financial Results ReleaseFebruary 10, 2025 | gurufocus.comBioCryst to Report Fourth Quarter 2024 Financial Results on February 24February 10, 2025 | globenewswire.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month High - What's Next?BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month High - Time to Buy?February 6, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 9.1% - Still a Buy?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 9.1% - Still a Buy?February 5, 2025 | marketbeat.comUnusually active option classes on open February 5thFebruary 5, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:BCRX)BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of some unusual options trading on Wednesday. Stock investors bought 6,158 call options on the company. This represents an increase of approximately 593% compared to the typical daily volume of 888 call options.February 5, 2025 | marketbeat.comSG Americas Securities LLC Has $311,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)SG Americas Securities LLC decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 74.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,350 shares of the biotechnology company's stocFebruary 5, 2025 | marketbeat.comBioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 4, 2025 | globenewswire.com3 Niche Healthcare Stocks Tackling Rare DiseasesFebruary 2, 2025 | stocknews.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest UpdateBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) saw a large decrease in short interest in January. As of January 15th, there was short interest totalling 15,720,000 shares, a decrease of 9.1% from the December 31st total of 17,290,000 shares. Based on an average daily volume of 2,050,000 shares, the short-interest ratio is currently 7.7 days.February 1, 2025 | marketbeat.comJMP Securities raises Pharvaris stock target to $55January 31, 2025 | msn.comJMP Securities maintains BioCryst stock with $18 targetJanuary 31, 2025 | msn.comBullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of StockJanuary 31, 2025 | finance.yahoo.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Earns "Market Outperform" Rating from JMP SecuritiesJMP Securities reissued a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday.January 31, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 5.6% - Still a Buy?BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 5.6% Higher - Still a Buy?January 27, 2025 | marketbeat.comInspire Investing LLC Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)Inspire Investing LLC reduced its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 66.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,479 shares of the biotechnJanuary 26, 2025 | marketbeat.comBioCryst (BCRX) Gets a Buy from RBC CapitalJanuary 23, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the six research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have assigned a buy raJanuary 23, 2025 | marketbeat.comJPMorgan Chase & Co. Trims Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)JPMorgan Chase & Co. lessened its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 22.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 577,129 shares of the biotechnology company's stock after selling 1January 18, 2025 | marketbeat.comBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decline in Short InterestBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 15,720,000 shares, a decline of 9.1% from the December 15th total of 17,290,000 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is presently 7.7 days.January 18, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4% - Time to Sell?BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4% - What's Next?January 16, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4% - Here's What HappenedBioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 3.4% - What's Next?January 14, 2025 | marketbeat.comBioCryst price target raised to $12 from $10 at Evercore ISIJanuary 14, 2025 | markets.businessinsider.comBioCryst: Strong Sales Performance and Future Growth Projections Lead to Buy RatingJanuary 14, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $12.00 Price Target at Evercore ISIEvercore ISI raised their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday.January 13, 2025 | marketbeat.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Given New $15.00 Price Target at Needham & Company LLCNeedham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday.January 13, 2025 | marketbeat.comBioCryst Pharmaceuticals: Continued Growth Driven by Orladeyo and Strategic Initiatives, Targeting $1 Billion Sales by 2030January 11, 2025 | markets.businessinsider.comBioCryst’s Strong Growth Prospects and Pipeline Developments Support Buy RatingJanuary 11, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)January 10, 2025 | finanznachrichten.deBioCryst (BCRX) Receives a Buy from RBC CapitalJanuary 10, 2025 | markets.businessinsider.comBioCryst Prel. Q4, FY24 Total Revenue, ORLADEYO Net Revenue IncreasesJanuary 10, 2025 | markets.businessinsider.comBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Here's WhyBioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up - Time to Buy?January 10, 2025 | marketbeat.comBioCryst Pharmaceuticals Inc (BCRX) Projects Strong Revenue Growth and New Drug Developments ...January 10, 2025 | gurufocus.comBioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)January 10, 2025 | globenewswire.com Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCRX Media Mentions By Week BCRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCRX News Sentiment▼0.150.60▲Average Medical News Sentiment BCRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCRX Articles This Week▼76▲BCRX Articles Average Week Get BioCryst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HALO News Today MDGL News Today ALKS News Today IONS News Today FOLD News Today LGND News Today DVAX News Today GERN News Today CLDX News Today MNKD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCryst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCryst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
